The Efficacy of Eradication of Helicobacter pylori Infection in Primary Prevention of NSAID-induced Gastropathy

S.M. Tkach, L.A. Onishchuk

Abstract


With the aim of clarifying the efficacy of eradication therapy for Helicobacter pylori (Hp) infection in primary prevention of NSAID-induced gastropathy, we have examined 39 Hp-positive patients, in whom we planned to administer non-steroidal anti-inflammatory drugs (NSAIDs) for various arthritis. In group I, non-steroidal anti-inflammatory drugs were prescribed after anti-helicobacter therapy, in group II eradication was not carried out, and the patients immediately received diclofenac. In both groups the incidence of peptic ulcers has been compared in 1 month after receiving diclofenac. In group I, peptic ulcers occurred in 2 patients (10.5 %), in group II — in 5 patients (26.3 %), ie in the group of eradication therapy they occurred significantly less frequently (χ2 = 0.5221). It is concluded that eradication of Hp-infection can be considered as an effective strategy for primary prevention of NSAID-induced gastropathy.


Keywords


NSAID-induced gastropathy; eradication of Helicobacter pylori infection

References


McNamara D. Gastro-oesophageal reflux disease and ulcer disease in Europe: NSAID-related gastroduodenal pathology / D. McNamara // The Burden of Gastrointestinal Diseases in Europe. — 2004. — P. 31-36.

Singh G. Epidemiology of NSAID-induced GI complications / G. Singh, G. Triadafilopoulus // J. Reumatol. — 1999. — Vol. 26. — P. 24-28.

Оf efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium / Case J.P., Baliunas A.J., Block J.A. Lack // Arch. Intern. Med. — 2003. — Vol. 163. — P. 169-178.

NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors / Micklewright R., Lane S., Linley W. // Aliment. Pharmacol. Ther. — 2003. — Vol. 17. — P. 321-332.

Myths and facts in the use of anti-inflammatory drugs / Hunt R.H., Lanas A., Stichtenoth D.O., Scarpignato C. // Ann. Med. — 2009. — 8. — 1-16.

Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis / Pincus T., Koch G., Lei H. [et al.] // Ann. Rheum. Dis. — 2004. — Vol. 63. — P. 931-939.

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs / Wolfe M.M., Lichtenstein D.R., G. Singh // N. Engl. J. Med. — 1999. — Vol. 340. — P. 1888-1899.

ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use / Bhatt D.L., Sheiman J., Abraham N.S. [et al.] // Am. J. Gastroenterol. — 2008. — 103. — 2890-2907.

Scarpignato C. Nonsteroidal anti-inflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention / C. Scarpignato, R.H. Hunt // Gastroenterol. Clin. North. Am. — 2010. — 39. — 433-464.

Chan F.K. NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management // Drug. Saf. — 2005. — Vol. 28. — P. 287-300.

Malfertheiner P. Management of Helicobacter pylori infection — Maastricht IV/Florence Consensus Report / Malferthei-ner P., Megraud F., O’Morain C. // Gut. — 2012. — Vol. 61. — P. 646-664.

Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users / Vergara M., Cata-

lan M., Gisbert J.P. [et al.] // Aliment. Pharmacol. Ther. — 2005. — Vol. 21. — P. 1411-18.

Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAID: double-blind, randomised, placebo-controlled trial / Lai K.C., Lau C.S., Ip W.Y. [et al.] // Aliment. Pharmacol. Ther. — 2003. — Vol. 17. — P. 799-805.

Primary prevention of diclofenac associated ulcers and dyspepsia by omeprasole or triple therapy in Helicobacter pylori-positive patients: a double-blind, randomised, placebo-controlled trial / Labenz J., Blum A.L., Bolten W.W. [et al.] // Gut. — 2002. — 51. — 329-335.

CYP2C19*17 Gain-of-Function Polymorphism Is Associa-ted With Peptic Ulcer Disease / Musumba C.O., Jorgensen A., Sutton L. [et al.] // Clinical pharmacology & Therapeutics. — 2013. — Vol. 93. — 2. — 195-203.




DOI: https://doi.org/10.22141/2308-2097.3.57.2015.81524

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru